Two Alzheimer’s drugs help patients live independently at home for longer periods
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.
News Medical on MSN5d
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?
Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...
CNN on MSN9d
How much longer you might live without assistance on new Alzheimer’s drugs
Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in ...
Medpage Today on MSN3d
Alzheimer's Patients May Gain Months of Independent Living With Treatment
Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...
Daily Herald7d
Elk Grove hospital hosts trials on potential new Alzheimer’s treatments
More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...
McKnight's Long-Term Care News3d
Study: Dementia scores can help inform use of monoclonal antibodies
Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...
Next-gen Alzheimer's drugs extend independent living by months
In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...
CNN9d
How much longer you might live without assistance on new Alzheimer’s drugs
Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...